期刊文献+

采用利奈唑胺治疗肺结核合并重症肺炎的临床疗效及安全性 被引量:19

The clinical efficacy and safety of pulmonary tuberculosis complicated with severe pneumonia treated by linezolid
下载PDF
导出
摘要 目的探讨利奈唑胺治疗肺结核合并重症肺炎的临床疗效及安全性。方法对我院2010年3月至2012年9月收治并经过临床确诊的肺结核合并重症肺炎患者50例进行回顾性分析,总结利奈唑胺的疗效,以及比较白细胞数、中性粒细胞数、C反应蛋白、红细胞沉降率、血小板、血肌酐在治疗前后的变化。计数资料应用配对t检验,P<0.05为差异有统计学意义。结果采用利奈唑胺治疗的肺结核合并重症肺炎患者50例中,细菌消除率和临床总有效率均为82.0%(41/50),白细胞数、中性粒细胞数、C反应蛋白、红细胞沉降率在治疗前分别为(14.52±6.88)×109/L、(12.44±7.01)×109/L、(112.28±82.59)μg/L、(66.28±37.71)mm/1h;治疗后分别为(9.94±3.43)×109/L、(7.64±3.46)×109/L、(57.19±59.23)μg/L、(50.56±27.15)mm/1h。治疗前后比较,差异有统计学意义,t值分别为4.214、4.345、3.163、2.098,P值均<0.05。血小板治疗前为(306.54±150.94)×109/L,治疗后为(259.18±140.39)×109/L,治疗前后比较,t=1.625,P=0.107;差异无统计学意义。血肌酐治疗前为(104.88±118.54)μmol/L,治疗后(118.15±122.18)μmol/L,t=-0.535,P=0.594;差异无统计学意义。结论利奈唑胺作为治疗肺结核合并重症肺炎的用药是安全有效的,可作为经验性用药。 Objective To study the clinical efficacy and safety of pulmonary tuberculosis complicated with severe pneumonia treated by linezolid.Methods Fifty cases of patients with pulmonary tuberculosis complicated with severe pneumonia,who were admitted to our hospital from March,2010 to September,2012,diagnosed by clinical data were retrospectively analyzed,in which the efficacy by linezolid was summarized and the values in leukocyte number,neutrophil count,C-reactive protein,erythrocyte sedimentation rate,platelets and serum creatinine were compared between before and after treatment.The paired t test was used for analysis of the enumeration data,in which P0.05 was considered statistically significance.Results In 50 patients with pulmonary tuberculosis complicated with severe pneumonia treated by linezolid,both the bacteria elimination rate and clinical cure rates were 82.0%(41/50).Their leukocyte number,neutrophil count,C-reactive protein,erythrocyte sedimentation before treatment were(14.52±6.88)×10^9/L,(12.44±7.01)×10^9/L,(112.28±82.59)μg/L and(66.28±37.71)mm/1 h,respectively before treatment and were(9.94±3.43)×10^9/L,(7.64±3.46)×10^9/L,(57.19±59.23)μg/L and(50.56±27.15)mm/1 h,respectively after treatment.There were significant differences between before and after treatment,in which t values were 4.214,4.345,3.163 and 2.098 and all P values were less than 0.05.The platelets count before treatment was(306.54±150.94)×10^9/L and after treatment was(259.18±140.39)×10^9/L,in which t value was 1.625,P value was 0.107;The blood creatinine concentrations were(104.88±118.54)μmol/L before treatment,(118.15±122.18)μmol/L after treatment,in which t value was-0.535,P value 0.594.No statistical differences were found between before and after treatment in platelets count and blood creatinine concentrations(all P values 0.05).Conclusion It is safe and effective for the patients with pulmonary tuberculosis complicated with severe pneumonia treated by linezolid,which can be used as empirical medication.
出处 《中国防痨杂志》 CAS 2013年第8期578-580,共3页 Chinese Journal of Antituberculosis
关键词 结核 并发症 肺炎 乙酰胺类 恶唑烷酮类 治疗结果 Tuberculosis pulmonary/complications Pneumonia Acetamides Oxazolidinones Treatment outcome
  • 相关文献

参考文献7

  • 1南光日,李冬.利奈唑胺临床应用分析[J].实用药物与临床,2009,12(6):403-405. 被引量:20
  • 2黄海荣,于霞,姜广路,戴广明,毕志强,马玙.利奈唑胺对分枝杆菌体外抑菌作用的初步研究[J].中华结核和呼吸杂志,2011,34(8):575-578. 被引量:28
  • 3National committee for clinical laboratory standards. Perfor- mance standards for antimicrobial susceptibility testing, twelfth informational supplement. M100 S12. Pennsylvania: NCCLS, 2002 : 1-133.
  • 4中华人民共和国卫生部,国家中医药管理局,解放军总后卫生部.卫医发[2004]285号抗菌药物临床应用指导原则.北京:中华人民共和国卫生部,2004.
  • 5Schecter GF,Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis, 2010, 50 (1) :49-55.
  • 6Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of line- zolid for the treatment of intractable multidrug resistant and extensively drug-resistant tuberculosis. J Antimicrob Che- mother, 2009,64(2) : 388 391.
  • 7黄海荣,于霞,姜广路,戴广明,马玙.利奈唑胺治疗耐多药结核病的初步评价[J].中国防痨杂志,2011,33(5):275-279. 被引量:26

二级参考文献45

  • 1Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilatorassociated pneumonia due to methicillin-resistant staphylococcus aureus[ J]. Chest,2008,134(6) :1200-1207.
  • 2Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin [J]. Intensive Care Med, 2004,30 (3) :388-394.
  • 3Ferrara AM. Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus [J].Int J Antimicrob Agents ,2007,30( 1 ) : 19-24.
  • 4Maclayton DO, Hall RG. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus [J]. Ann Pharmaeother, 2007,41 ( 2 ) : 235- 244.
  • 5Hau T. Efficacy and Safety of Linezolid in the Treatment of Skin and Soft Tissue Infections[ J]. Eur J Clin Microbiol Infect Dis,2002,21 (7) :491-498.
  • 6John W, Kamal I, Dennis S, et al. Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections[J]. Antimicrobial Agents And Chemotherapy, 2005,49 ( 11 ) :2260-2266.
  • 7Hachem R, Afif C, Gokaslan Z, et al. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid[J]. Eur J Clin Microbiol Infect Dis,2001,20(6): 432-434.
  • 8Cindy M, Lisa L, Denise H, et al. Linezolid : Implications for neurosurgical infections [J]. Neurological Research, 2003,25 ( 1 ) :22-26.
  • 9Lin YH, Wu VC,Tsai IJ,et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency[ J]. Int J Antimicrob Agents,2006,28 (4) :345-351.
  • 10Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, dfampin, and renal function on hematological adverse events induced by linezolid [J]. Antimicrob Agents Chemother,2007,51 (7) :2559-2563.

共引文献66

同被引文献124

  • 1邹级谦.肺结核诊断标准[J].结核病健康教育,2008(1):7-9. 被引量:41
  • 2中华人民共和国卫生部,国家中医药管理局,解放军总后勤部卫生部.关于施行《抗菌药物临床应用指导原则》的通知[J].中华医学杂志,2004,84(22):1857-1857. 被引量:109
  • 3郑百成,方银芬.516例肺结核继发呼吸道感染痰普通细菌培养分析[J].临床肺科杂志,2007,12(4):399-400. 被引量:15
  • 4Wadhwa N, Chandran A, Aneja S, et al. Efficacy of zinc given as an adjunct in the treatment of severe and very severe pneumonia in hospitalized chil- dren 2 - 24 mo of age : a randomized, double - blind, placebo - controlled trial[J ]. Am J Clin Nutr,2013,97 (6) :1 387 - 1 394.
  • 5Nantongo JM, Wobudeya E, Mupere E, et al. High incidence of pulmonary tuberculosis in children admitted with severe pneumonia in Uganda[J]. BMC Pediatr,2013,13 (1) : 16.
  • 6Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of line- zolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus[J] .Antimicrob Agents Chemother, 2010,54 (10) : 4 394 - 4 400.
  • 7de Pascale G, Bello G,Tumbarello M, et al. Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the litera- ture[J]. Curt Opin Pulm Med,2012,18 (3) :213 - 221.
  • 8Oliwa JN,Karumbi JM,Marais BJ,et al.Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas:a systematic review[J].Lancet Respir Med,2015,3(3):235-243.
  • 9Shaw KJ,Barbachyn MR.The oxazolidinones:past,present,and future[J].Ann N Y Acad Sci,2011,1241:48-70.
  • 10Wunderink RG,Niederman MS,Kollef MH,et al.Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia:a randomized,controlled study[J].Clin Infect Dis,2012,54(5):621-629.

引证文献19

二级引证文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部